Skip to content
  • Resources
    • cilcare’s publications
    • cilcare’s scientific posters
    • Latest Scientific Literature
    • Grant Calls
  • News
    • news
    • newsletter
  • Investors 
  • Careers
  • Contact
  • Resources
    • cilcare’s publications
    • cilcare’s scientific posters
    • Latest Scientific Literature
    • Grant Calls
  • News
    • news
    • newsletter
  • Investors 
  • Careers
  • Contact
  • X
  • en_US
  • ja
  • en_US
  • ja
  • About cilcare
    • Who we are
    • Our team
    • Scientific advisors
    • Hearing loss & Aging connection
  • External Innovation

    Pharmacokinetics & distribution

    PK & Distribution
    Bioanalysis
    Vectors & gene therapy distribution
    Biomarker studies

    Behavioral tests

    Tinnitus detection
    GPIAS & PPI
    Hyperacusis

    Delivery capabilities

    Transtympanic
    Intracochlear
    Systemic

    Surgery

    Inner ear surgery
    Cochlear implantation
    Brain Electrode implantation
    Other otic surgery

    Screening / dose selection for ototoxicity or otoprotection

    In vitro on Otic cell line
    Ex vivo on Cochlear explants
    In vivo in Zebrafish

    Formulation

    Formulation for otic delivery

    Animal models

    Noise-induced hearing loss
    Synaptopathy
    Cisplatin-induced ototoxicity
    Antibiotic-induced ototoxicity
    Ouabain-induced auditory neuropathy
    Salicylate-induced tinnitus
    Other disease & transgenic models
    Rodent & large species

    Our missions

    In vivo studies

    Auditory efficacy studies
    Auditory tolerance & safety studies
    Auditory phenotyping studies
    GLP Ototoxicity studies / GLP Toxicology & Toxicokinetics

    Modalities

    Small molecules, peptides, antibodies, large molecules
    Gene & cell therapies
    Cochlear implants, implantable devices, drug-eluting electrodes

    Electrophysiology & electroacoustic

    ABR
    DPOAE
    Wave I to V analysis
    CAP & unicellular electrophysiology

    Ear assessment

    Otoscopy
    Tympanometry
    Gross middle ear assessment

    Pathology & histopathology

    Histology of the ear
    Cytocochleogram
    Histology of other organs
    Microscopy & imaging

    Molecular biology & biochemistry

    Biochemistry
    Molecular biology

    OUR MISSIONS

    IN VITRO / EX VIVO / IN VIVO EFFICACY

    FORMULATION & DISTRIBUTION

    OTOTOXICITY

    CLINICAL AUDITORY BIOMARKER

    > In vitro / ex vivo assays

    In vitro on Otic cell line
    Ex vivo on Cochlear explants

    > In vivo models

    Zebrasfish, Rodents & Large species
    Noise-induced hearing loss
    Synaptopathy
    Cisplatin-induced ototoxicity
    Antibiotic-induced ototoxicity
    Ouabain-induced auditory neuropathy
    Salicylate-induced tinnitus
    Other diseases & transgenic models

    > Hearing measurements & behavioral tests

    Otoscopy
    ABR
    Wave I to V analysis
    DPOAE
    Tympanometry
    Tinnitus detection
    GPIAS & PPI
    Hyperacusis
    CAP & unicellular electrophysiology
    Molecular Biology & Biochemistry
    Preclinical biomarkers
    Auditory phenotyping

    > Pathology & Histopathology

    Gross middle ear assessment
    Histology of the ear
    Cytocochleogram
    Histology of other organs
    Microscopy & imaging

    > Surgery

    Inner ear surgery
    Cochlear implantation
    Brain Electrode implantation
    Other otic surgeries

    > Formulation for otic delivery

    > Otic drug, vector & gene therapy administration

    Middle ear
    Intracochlear
    Systemic

    > Inner ear PK studies

    > PK studies for other therapeutic indications

    > Vectors & gene therapy distribution

    > Therapeutic modalities

    Small molecules, peptides, antibodies, large molecules
    Gene & cell therapies
    Cochlear implants, implantable devices, drug-eluting electrodes

    > Auditory tolerance & safety studies

    > GLP Ototoxicity studies / GLP Toxicology & Toxicokinetics

    > Human hearing measurements

    > Auditory biomarkers in clinical trials

    > In vitro / ex vivo assays

    In vitro on Otic cell line
    Ex vivo on Cochlear explants

    > In vivo models

    Zebrasfish, Rodents & Large species
    Noise-induced hearing loss
    Synaptopathy
    Cisplatin-induced ototoxicity
    Antibiotic-induced ototoxicity
    Ouabain-induced auditory neuropathy
    Salicylate-induced tinnitus
    Other diseases & transgenic models

    > Hearing measurements & behavioral tests

    Otoscopy
    ABR
    Wave I to V analysis
    DPOAE
    Tympanometry
    Tinnitus detection
    GPIAS & PPI
    Hyperacusis
    CAP & unicellular electrophysiology
    Molecular Biology & Biochemistry
    Preclinical biomarkers
    Auditory phenotyping

    > Pathology & Histopathology

    Gross middle ear assessment
    Histology of the ear
    Cytocochleogram
    Histology of other organs
    Microscopy & imaging

    > Surgery

    Inner ear surgery
    Cochlear implantation
    Brain Electrode implantation
    Other otic surgery

    > Formulation for otic delivery

    > Otic drug, vector & gene therapy administration

    Transtympanic
    Intracochlear
    Systemic

    > Inner ear PK studies

    > PK studies for other therapeutic indications

    > Vectors & gene therapy distribution

    > Therapeutic modalities

    Small molecules, peptides, antibodies, large molecules
    Gene & cell therapies
    Cochlear implants, implantable devices, drug-eluting electrodes

    > Auditory tolerance & safety studies

    > GLP Ototoxicity studies / GLP Toxicology & Toxicokinetics

    > Human hearing measurements

    > Clinical biomarker studies

  • Therapeutics
    • Our missions
    • Our pipeline
    • Cochlear synaptopathy
    • Our clinical studies
  • Auditory Analytics
  • About cilcare
    • Who we are
    • Our team
    • Scientific advisors
    • Hearing loss & Aging connection
  • External Innovation
  • Therapeutics
    • Our missions
    • Our pipeline
    • Cochlear synaptopathy
    • Our clinical studies
  • Auditory Analytics
  • About cilcare
    • Who we are
    • Our team
    • Scientific advisors
    • Hearing loss & Aging connection
  • External Innovation
  • Therapeutics
    • Our missions
    • Our pipeline
    • Cochlear synaptopathy
    • Our clinical studies
  • Auditory Analytics
Fichier 2
Read more about the article CILcare invites you in Basel to a first-of-its-kind workshop about the auditory system dysfunctions, May 2018

CILcare invites you in Basel to a first-of-its-kind workshop about the auditory system dysfunctions, May 2018

  • Post author:CILcare
  • Post published:13 March 2018
  • Post category:Events

Register by May 9th to attend !  

Continue ReadingCILcare invites you in Basel to a first-of-its-kind workshop about the auditory system dysfunctions, May 2018
Read more about the article Discover a recent Editorial featuring intracochlear drug delivery systems, by CILcare & Draper Inc.

Discover a recent Editorial featuring intracochlear drug delivery systems, by CILcare & Draper Inc.

  • Post author:CILcare
  • Post published:12 March 2018
  • Post category:Events

The article draws the latest advances in drug development for hearing loss with challenges of delivery routes and emerging innovative devices. Here is the link to the article published on…

Continue ReadingDiscover a recent Editorial featuring intracochlear drug delivery systems, by CILcare & Draper Inc.
Read more about the article CILcare at the world CNS Summit in Boston, February 2018

CILcare at the world CNS Summit in Boston, February 2018

  • Post author:CILcare
  • Post published:25 January 2018
  • Post category:Events

Dr. Gaëlle Naert, COO, will be visiting the 6th world CNS summit taking place in Boston between 20-22 February 2018. Join us at this event to discuss the link between…

Continue ReadingCILcare at the world CNS Summit in Boston, February 2018
Read more about the article CILcare will exhibit at the ARO 2018

CILcare will exhibit at the ARO 2018

  • Post author:CILcare
  • Post published:3 January 2018
  • Post category:Events

CILcare will exhibit at ARO 2018 Our team invites you to meet us at the MidWinter meeting of the Association for Research in Otolaryngology on the 10-12 February 2018 at…

Continue ReadingCILcare will exhibit at the ARO 2018
Read more about the article CILcare will share its experience at the next Café des Sciences in Boston !

CILcare will share its experience at the next Café des Sciences in Boston !

  • Post author:CILcare
  • Post published:3 January 2018
  • Post category:Events

Come and join us at the Café des Sciences on the 24th January in Boston ! You will learn more about hearing and the latest research advances to find new…

Continue ReadingCILcare will share its experience at the next Café des Sciences in Boston !
Read more about the article CILcare appointed Cyrille Sage, Ph.D, as R&D Project Manager for the safety unit platform in Boston

CILcare appointed Cyrille Sage, Ph.D, as R&D Project Manager for the safety unit platform in Boston

  • Post author:CILcare
  • Post published:11 December 2017
  • Post category:Events

LEXINGTON, Mass., CILcare Inc announced that it has appointed Dr. Cyrille Sage as R&D Project Manager. Dr. Sage has nearly 20 years of experience in inner hair cells research, conducting…

Continue ReadingCILcare appointed Cyrille Sage, Ph.D, as R&D Project Manager for the safety unit platform in Boston
Read more about the article World Pharma Today: Auditory Therapy, Ototoxicity and GLP Compliance

World Pharma Today: Auditory Therapy, Ototoxicity and GLP Compliance

  • Post author:CILcare
  • Post published:7 November 2017
  • Post category:Events

Will the promising market for ear disorder treatments follow ophthalmology’s dramatic growth curve? Discover the article by Marie-Pierre Pasdelou, founder & CDO, CILcare, and Michael Naimark, Director of Business Development,…

Continue ReadingWorld Pharma Today: Auditory Therapy, Ototoxicity and GLP Compliance
Read more about the article CILcare, CBSET, and Draper partner to accelerate hearing loss treatment and care

CILcare, CBSET, and Draper partner to accelerate hearing loss treatment and care

  • Post author:CILcare
  • Post published:6 November 2017
  • Post category:Events

Industry consortium is dedicated to the translation of novel drug delivery devices for emerging treatments in hearing loss CAMBRIDGE, Mass., Nov. 6, 2017 – CILcare Inc., the world’s leading clinical…

Continue ReadingCILcare, CBSET, and Draper partner to accelerate hearing loss treatment and care
Read more about the article CILcare at BIO Europe in Berlin, 6-8 November 2017

CILcare at BIO Europe in Berlin, 6-8 November 2017

  • Post author:CILcare
  • Post published:27 September 2017
  • Post category:Events

We invite you to meet us at the 23rd Europe's largest partnering conference !

Continue ReadingCILcare at BIO Europe in Berlin, 6-8 November 2017
Read more about the article CILcare sponsors the 1st International Symposium on Inner Ear Therapies (Marrakech, 1-3 November 2017)

CILcare sponsors the 1st International Symposium on Inner Ear Therapies (Marrakech, 1-3 November 2017)

  • Post author:CILcare
  • Post published:7 August 2017
  • Post category:Events

CILcare invites you to the first International Symposium on Inner Ear Therapies (ISIET) taking place in Marrakech, Morocco, between 1 and 3 November 2017. Join us to discuss about the latest…

Continue ReadingCILcare sponsors the 1st International Symposium on Inner Ear Therapies (Marrakech, 1-3 November 2017)
  • Go to the previous page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 16
  • Go to the next page
Linkedin-in X
  • About cilcare
  • External innovation
  • Therapeutics
  • Auditory Analytics
  • Resources
  • Partners
  • News
  • Contact
  • About cilcare
  • External innovation
  • Therapeutics
  • Auditory Analytics
  • Resources
  • Partners
  • News
  • Contact
cilcare
MONTPELLIER • BOSTON • PARIS

info@cilcare.com

Intra-Community VAT: FR00803146125

cilcare | Mentions légales | Conception : Malice | Développement : Linov ©2026
  • About cilcare
    • Who we are
    • Our team
    • Scientific advisors
    • Hearing loss & Aging connection
  • External Innovation
  • Therapeutics
    • Our missions
    • Our pipeline
    • Cochlear synaptopathy
    • Our clinical studies
  • Auditory Analytics
  • About cilcare
    • Who we are
    • Our team
    • Scientific advisors
    • Hearing loss & Aging connection
  • External Innovation
  • Therapeutics
    • Our missions
    • Our pipeline
    • Cochlear synaptopathy
    • Our clinical studies
  • Auditory Analytics
About cilcare
Who we are
Our team
Scientific advisors
Hearing loss & Aging connection
External Innovation

Pharmacokinetics & distribution

PK & Distribution
Bioanalysis
Vectors & gene therapy distribution
Biomarker studies

Behavioral tests

Tinnitus detection
GPIAS & PPI
Hyperacusis

Delivery capabilities

Transtympanic
Intracochlear
Systemic

Surgery

Inner ear surgery
Cochlear implantation
Brain Electrode implantation
Other otic surgery

Screening / dose selection for ototoxicity or otoprotection

In vitro on Otic cell line
Ex vivo on Cochlear explants
In vivo in Zebrafish

Formulation

Formulation for otic delivery

Animal models

Noise-induced hearing loss
Synaptopathy
Cisplatin-induced ototoxicity
Antibiotic-induced ototoxicity
Ouabain-induced auditory neuropathy
Salicylate-induced tinnitus
Other disease & transgenic models
Rodent & large species

Our missions

In vivo studies

Auditory efficacy studies
Auditory tolerance & safety studies
Auditory phenotyping studies
GLP Ototoxicity studies / GLP Toxicology & Toxicokinetics

Modalities

Small molecules, peptides, antibodies, large molecules
Gene & cell therapies
Cochlear implants, implantable devices, drug-eluting electrodes

Electrophysiology & electroacoustic

ABR
DPOAE
Wave I to V analysis
CAP & unicellular electrophysiology

Ear assessment

Otoscopy
Tympanometry
Gross middle ear assessment

Pathology & histopathology

Histology of the ear
Cytocochleogram
Histology of other organs
Microscopy & imaging

Molecular biology & biochemistry

Biochemistry
Molecular biology

OUR MISSIONS

IN VITRO / EX VIVO / IN VIVO EFFICACY

FORMULATION & DISTRIBUTION

OTOTOXICITY

CLINICAL AUDITORY BIOMARKER

> In vitro / ex vivo assays

In vitro on Otic cell line
Ex vivo on Cochlear explants

> In vivo models

Zebrasfish, Rodents & Large species
Noise-induced hearing loss
Synaptopathy
Cisplatin-induced ototoxicity
Antibiotic-induced ototoxicity
Ouabain-induced auditory neuropathy
Salicylate-induced tinnitus
Other diseases & transgenic models

> Hearing measurements & behavioral tests

Otoscopy
ABR
Wave I to V analysis
DPOAE
Tympanometry
Tinnitus detection
GPIAS & PPI
Hyperacusis
CAP & unicellular electrophysiology
Molecular Biology & Biochemistry
Preclinical biomarkers
Auditory phenotyping

> Pathology & Histopathology

Gross middle ear assessment
Histology of the ear
Cytocochleogram
Histology of other organs
Microscopy & imaging

> Surgery

Inner ear surgery
Cochlear implantation
Brain Electrode implantation
Other otic surgeries

> Formulation for otic delivery

> Otic drug, vector & gene therapy administration

Middle ear
Intracochlear
Systemic

> Inner ear PK studies

> PK studies for other therapeutic indications

> Vectors & gene therapy distribution

> Therapeutic modalities

Small molecules, peptides, antibodies, large molecules
Gene & cell therapies
Cochlear implants, implantable devices, drug-eluting electrodes

> Auditory tolerance & safety studies

> GLP Ototoxicity studies / GLP Toxicology & Toxicokinetics

> Human hearing measurements

> Auditory biomarkers in clinical trials

> In vitro / ex vivo assays

In vitro on Otic cell line
Ex vivo on Cochlear explants

> In vivo models

Zebrasfish, Rodents & Large species
Noise-induced hearing loss
Synaptopathy
Cisplatin-induced ototoxicity
Antibiotic-induced ototoxicity
Ouabain-induced auditory neuropathy
Salicylate-induced tinnitus
Other diseases & transgenic models

> Hearing measurements & behavioral tests

Otoscopy
ABR
Wave I to V analysis
DPOAE
Tympanometry
Tinnitus detection
GPIAS & PPI
Hyperacusis
CAP & unicellular electrophysiology
Molecular Biology & Biochemistry
Preclinical biomarkers
Auditory phenotyping

> Pathology & Histopathology

Gross middle ear assessment
Histology of the ear
Cytocochleogram
Histology of other organs
Microscopy & imaging

> Surgery

Inner ear surgery
Cochlear implantation
Brain Electrode implantation
Other otic surgery

> Formulation for otic delivery

> Otic drug, vector & gene therapy administration

Transtympanic
Intracochlear
Systemic

> Inner ear PK studies

> PK studies for other therapeutic indications

> Vectors & gene therapy distribution

> Therapeutic modalities

Small molecules, peptides, antibodies, large molecules
Gene & cell therapies
Cochlear implants, implantable devices, drug-eluting electrodes

> Auditory tolerance & safety studies

> GLP Ototoxicity studies / GLP Toxicology & Toxicokinetics

> Human hearing measurements

> Clinical biomarker studies

Therapeutics
Our missions
Our pipeline
Cochlear synaptopathy
Our clinical studies
Auditory Analytics
  • en_US
  • ja
  • en_US
  • ja
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok